Aamund regrets overly-ambitious strategy in Neurosearch
From the outset, Neurosearch reached for the stars. The aim was drugs for widespread diseases such as cancer, depression and Alzheimer’s, but that strategy should have included another branch – niche medicine, admits Asger Aamund, who is co-founder and former chairman of the board in Neurosearch.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app